{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:21Z","timestamp":1792788021284,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Medical Award Fund","award":["YXJL-2020-0785-0655"],"award-info":[{"award-number":["YXJL-2020-0785-0655"]}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82103493"],"award-info":[{"award-number":["82103493"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Postdoctoral Fellowship Program of CPSF","award":["GZB20230041"],"award-info":[{"award-number":["GZB20230041"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07386-2","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T11:43:45Z","timestamp":1763034225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Glutamine metabolism reprogramming promotes bladder cancer progression via PYCR1: a multi-omics and functional validation study"],"prefix":"10.1186","volume":"23","author":[{"given":"Xinjia","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enkui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0317-3148","authenticated-orcid":false,"given":"Shikai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"7386_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, Theodorescu D. Bladder cancer. Nat Rev Dis Primers. 2023;9:58.","journal-title":"Nat Rev Dis Primers"},{"key":"7386_CR2","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","volume":"400","author":"E Comp\u00e9rat","year":"2022","unstructured":"Comp\u00e9rat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, Stenzl A, Thoeny HC, Witjes JA. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 2022;400:1712\u201321.","journal-title":"Lancet"},{"key":"7386_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, Max Bruins H, Carri\u00f3n A, Cathomas R, Comp\u00e9rat E, Efstathiou JA, Fietkau R, Gakis G, Lorch A, Martini A, Mertens LS, Meijer RP, Milowsky MI, Neuzillet Y, Panebianco V, Redlef J, Rink M, Rouanne M, Thalmann GN, S\u00e6bj\u00f8rnsen S. Veskim\u00e4e E and Van der Heijden AG. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol. 2024;85:17\u201331.","journal-title":"Eur Urol"},{"key":"7386_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ccell.2021.04.012","volume":"39","author":"M Knowles","year":"2021","unstructured":"Knowles M, Dyrskj\u00f8t L, Heath EI, Bellmunt J, Siefker-Radtke AO. Metastatic urothelial carcinoma. Cancer Cell. 2021;39:583\u20135.","journal-title":"Cancer Cell"},{"key":"7386_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","volume":"34","author":"AV Balar","year":"2023","unstructured":"Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Necchi A, Petrylak DP, Plimack ER, Xu JZ, Imai K, Moreno BH, Bellmunt J, de Wit R, O\u2019Donnell PH. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol. 2023;34:289\u201399.","journal-title":"Ann Oncol"},{"key":"7386_CR6","doi-asserted-by":"crossref","unstructured":"Li K, Zhong W, Fan J, Wang S, Yu D, Xu T, Lyu J, Wu S, Qin T, Wu Z, Xu L, Wu K, Liu Z, Hu Z, Li F, Wang J, Wang Q, Min J, Zhang Z, Yu L, Ding S, Huang L, Zhao T, Huang J, Lin T. Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial. Nat Cancer. 2024.","DOI":"10.1038\/s43018-024-00822-0"},{"key":"7386_CR7","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1200\/JCO.23.00363","volume":"41","author":"R Cathomas","year":"2023","unstructured":"Cathomas R, Rothschild SI, Hayoz S, Bubendorf L, \u00d6zdemir BC, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel RT, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M. Petrausch U. Perioperative chemoimmunotherapy with durvalumab for Muscle-Invasive urothelial carcinoma: primary analysis of the Single-Arm phase II trial SAKK 06\/17. J Clin Oncol. 2023;41:5131\u20139.","journal-title":"J Clin Oncol"},{"key":"7386_CR8","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.21.01485","volume":"40","author":"SA Funt","year":"2022","unstructured":"Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, Lee CH, Aggen D, Zimmerman D, McHugh D, Apollo A, Durdin TD, Truong H, Kamradt J, Khalil M, Lash B, Ostrovnaya I, McCoy AS, Hettich G, Regazzi A, Jihad M, Ratna N, Boswell A, Francese K, Yang Y, Folefac E, Herr HW, Donat SM, Pietzak E, Cha EK, Donahue TF, Goh AC, Huang WC, Bajorin DF, Iyer G, Bochner BH, Balar AV. Mortazavi A and Rosenberg JE. Neoadjuvant Atezolizumab with gemcitabine and cisplatin in patients with Muscle-Invasive bladder cancer: A Multicenter, Single-Arm, phase II trial. J Clin Oncol. 2022;40:1312\u201322.","journal-title":"J Clin Oncol"},{"key":"7386_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J, Zhao P, Fang L, Shi Y, Wang P. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther. 2023;8:104.","journal-title":"Signal Transduct Target Ther"},{"key":"7386_CR10","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1080\/21655979.2022.2033382","volume":"13","author":"Y Pei","year":"2022","unstructured":"Pei Y, Zhang H, Lu K, Tang X, Li J, Zhang E, Zhang J, Huang Y, Yang Z, Lu Z, Li Y, Zhang H, Dong L. Circular RNA circRNA_0067934 promotes glioma development by modulating the MicroRNA miR-7\/ Wnt\/\u03b2-catenin axis. Bioengineered. 2022;13:5792\u2013802.","journal-title":"Bioengineered"},{"key":"7386_CR11","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.2174\/1381612829666230622140926","volume":"29","author":"K Chen","year":"2023","unstructured":"Chen K, Zhang J, Beeraka NM, Li J, Sinelnikov MY, Zhang X, Cao Y, Zakharova DK, Nikolenko VN, Reshetov IV, Lu P. Novel perspectives on Nanotechnological and biomedical implications of monotherapy or combination regimen of lactoferrin. Curr Pharm Des. 2023;29:1579\u201391.","journal-title":"Curr Pharm Des"},{"key":"7386_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.immuni.2015.09.001","volume":"43","author":"SK Biswas","year":"2015","unstructured":"Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43:435\u201349.","journal-title":"Immunity"},{"key":"7386_CR13","doi-asserted-by":"crossref","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368.","DOI":"10.1126\/science.aaw5473"},{"key":"7386_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.tem.2019.03.003","volume":"30","author":"E Bernfeld","year":"2019","unstructured":"Bernfeld E, Foster DA. Glutamine as an essential amino acid for KRas-Driven cancer cells. Trends Endocrinol Metab. 2019;30:357\u201368.","journal-title":"Trends Endocrinol Metab"},{"key":"7386_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","volume":"21","author":"PS Ward","year":"2012","unstructured":"Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297\u2013308.","journal-title":"Cancer Cell"},{"key":"7386_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12964-024-02018-6","volume":"23","author":"D Nan","year":"2025","unstructured":"Nan D, Yao W, Huang L, Liu R, Chen X, Xia W, Sheng H, Zhang H, Liang X, Lu Y. Glutamine and cancer: metabolism, immune microenvironment, and therapeutic targets. Cell Commun Signal. 2025;23:45.","journal-title":"Cell Commun Signal"},{"key":"7386_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13046-024-02994-0","volume":"43","author":"B Wang","year":"2024","unstructured":"Wang B, Pei J, Xu S, Liu J, Yu J. A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle. J Exp Clin Cancer Res. 2024;43:74.","journal-title":"J Exp Clin Cancer Res"},{"key":"7386_CR18","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","volume":"18","author":"G Sj\u00f6dahl","year":"2012","unstructured":"Sj\u00f6dahl G, Lauss M, L\u00f6vgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fern\u00f6 M, Ringn\u00e9r M, M\u00e5nsson W, Liedberg F. Lindgren D and H\u00f6glund M. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18:3377\u201386.","journal-title":"Clin Cancer Res"},{"key":"7386_CR19","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-11-2271","volume":"18","author":"M Riester","year":"2012","unstructured":"Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, Bochner BH, Michor F. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res. 2012;18:1323\u201333.","journal-title":"Clin Cancer Res"},{"key":"7386_CR20","doi-asserted-by":"publisher","first-page":"e38863","DOI":"10.1371\/journal.pone.0038863","volume":"7","author":"D Lindgren","year":"2012","unstructured":"Lindgren D, Sj\u00f6dahl G, Lauss M, Staaf J, Chebil G, L\u00f6vgren K, Gudjonsson S, Liedberg F, Patschan O, M\u00e5nsson W. Fern\u00f6 M and H\u00f6glund M. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS ONE. 2012;7:e38863.","journal-title":"PLoS ONE"},{"key":"7386_CR21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","volume":"81","author":"G Sj\u00f6dahl","year":"2022","unstructured":"Sj\u00f6dahl G, Abrahamsson J, Holmsten K, Bernardo C, Chebil G, Eriksson P, Johansson I, Kollberg P, Lindh C, L\u00f6vgren K, Marzouka NA, Olsson H, H\u00f6glund M. Ull\u00e9n A and Liedberg F. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol. 2022;81:523\u201332.","journal-title":"Eur Urol"},{"key":"7386_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Dur\u00e1n I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Th\u00e5str\u00f6m A, Abidoye OO, Fine GD, Bajorin DF. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67\u201376.","journal-title":"Lancet"},{"key":"7386_CR23","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Mart\u00edn-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr., Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE. Weinhold N and Chan TA. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171:934\u2013e949916.","journal-title":"Cell"},{"key":"7386_CR24","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013102.","journal-title":"Nucleic Acids Res"},{"key":"7386_CR25","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1002\/sim.5958","volume":"32","author":"P Blanche","year":"2013","unstructured":"Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32:5381\u201397.","journal-title":"Stat Med"},{"key":"7386_CR26","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, Fu X, Liu S, Bo X, Yu G. ClusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov (Camb). 2021;2:100141.","journal-title":"Innov (Camb)"},{"key":"7386_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"key":"7386_CR28","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, Trevi\u00f1o V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RGW. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"key":"7386_CR29","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/ijc.33794","volume":"149","author":"H Lai","year":"2021","unstructured":"Lai H, Cheng X, Liu Q, Luo W, Liu M, Zhang M, Miao J, Ji Z, Lin GN, Song W, Zhang L, Bo J, Yang G, Wang J, Gao WQ. Single-cell RNA sequencing reveals the epithelial cell heterogeneity and invasive subpopulation in human bladder cancer. Int J Cancer. 2021;149:2099\u2013115.","journal-title":"Int J Cancer"},{"key":"7386_CR30","doi-asserted-by":"publisher","first-page":"100814","DOI":"10.1016\/j.neo.2022.100814","volume":"31","author":"M Conde","year":"2022","unstructured":"Conde M, Frew IJ. Therapeutic significance of ARID1A mutation in bladder cancer. Neoplasia. 2022;31:100814.","journal-title":"Neoplasia"},{"key":"7386_CR31","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ, Weinstein JN. Kwiatkowski DJ and Lerner SP. Comprehensive molecular characterization of Muscle-Invasive bladder cancer. Cell. 2017;171:540\u2013e556525.","journal-title":"Cell"},{"key":"7386_CR32","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ng.3557","volume":"48","author":"J Kim","year":"2016","unstructured":"Kim J, Mouw KW, Polak P, Braunstein LZ, Kamburov A, Kwiatkowski DJ, Rosenberg JE, Van Allen EM. D\u2019Andrea A and Getz G. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016;48:600\u20136.","journal-title":"Nat Genet"},{"key":"7386_CR33","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1038\/s42255-023-00919-3","volume":"5","author":"SJ Linder","year":"2023","unstructured":"Linder SJ, Bernasocchi T, Mart\u00ednez-Pastor B, Sullivan KD, Galbraith MD, Lewis CA, Ferrer CM, Boon R, Silveira GG, Cho HM, Vidoudez C, Shroff S, Oliveira-Costa JP, Ross KN, Massri R, Matoba Y, Kim E, Rueda BR, Stott SL, Gottlieb E, Espinosa JM, Mostoslavsky R. Inhibition of the proline metabolism rate-limiting enzyme P5CS allows proliferation of glutamine-restricted cancer cells. Nat Metab. 2023;5:2131\u201347.","journal-title":"Nat Metab"},{"key":"7386_CR34","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1126\/science.aav2588","volume":"366","author":"RD Leone","year":"2019","unstructured":"Leone RD, Zhao L, Englert JM, Sun IM, Oh MH, Sun IH, Arwood ML, Bettencourt IA, Patel CH, Wen J, Tam A, Blosser RL, Prchalova E, Alt J, Rais R, Slusher BS, Powell JD. Glutamine Blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366:1013\u201321.","journal-title":"Science"},{"key":"7386_CR35","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12964-022-00909-0","volume":"20","author":"G Ma","year":"2022","unstructured":"Ma G, Zhang Z, Li P, Zhang Z, Zeng M, Liang Z, Li D, Wang L, Chen Y, Liang Y, Niu H. Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment. Cell Commun Signal. 2022;20:114.","journal-title":"Cell Commun Signal"},{"key":"7386_CR36","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1038\/s41388-024-03059-4","volume":"43","author":"AK Beier","year":"2024","unstructured":"Beier AK, Ebersbach C, Siciliano T, Scholze J, Hofmann J, H\u00f6nscheid P, Baretton GB, Woods K, Guezguez B, Dubrovska A, Markowitsch SD, Thomas C, Puhr M, Erb HHH. Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer. Oncogene. 2024;43:2038\u201350.","journal-title":"Oncogene"},{"key":"7386_CR37","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrc3557","volume":"13","author":"JW Locasale","year":"2013","unstructured":"Locasale JW. Serine, Glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer. 2013;13:572\u201383.","journal-title":"Nat Rev Cancer"},{"key":"7386_CR38","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/nrc.2016.71","volume":"16","author":"BJ Altman","year":"2016","unstructured":"Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16:619\u201334.","journal-title":"Nat Rev Cancer"},{"key":"7386_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2016.08.009","volume":"25","author":"GS Ducker","year":"2017","unstructured":"Ducker GS, Rabinowitz JD. One-Carbon metabolism in health and disease. Cell Metab. 2017;25:27\u201342.","journal-title":"Cell Metab"},{"key":"7386_CR40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrurol.2017.11","volume":"14","author":"AP Glaser","year":"2017","unstructured":"Glaser AP, Fantini D, Shilatifard A, Schaeffer EM, Meeks JJ. The evolving genomic landscape of urothelial carcinoma. Nat Rev Urol. 2017;14:215\u201329.","journal-title":"Nat Rev Urol"},{"key":"7386_CR41","doi-asserted-by":"publisher","first-page":"643282","DOI":"10.3389\/fimmu.2021.643282","volume":"12","author":"YH Pan","year":"2021","unstructured":"Pan YH, Zhang JX, Chen X, Liu F, Cao JZ, Chen Y, Chen W, Luo JH. Predictive value of the TP53\/PIK3CA\/ATM mutation classifier for patients with bladder cancer responding to immune checkpoint inhibitor therapy. Front Immunol. 2021;12:643282.","journal-title":"Front Immunol"},{"key":"7386_CR42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41588-024-02015-y","volume":"57","author":"N Wang","year":"2025","unstructured":"Wang N, Pachai MR, Li D, Lee CJ, Warda S, Khudoynazarova MN, Cho WH, Xie G, Shah SR, Yao L, Qian C, Wong EWP, Yan J, Tomas FV, Hu W, Kuo F, Gao SP, Luo J, Smith AE, Han M, Gao D, Ge K, Yu H, Chandarlapaty S, Iyer GV, Rosenberg JE, Solit DB, Al-Ahmadie HA, Chi P, Chen Y. Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters. Nat Genet. 2025;57:165\u201379.","journal-title":"Nat Genet"},{"key":"7386_CR43","doi-asserted-by":"crossref","unstructured":"Schl\u00f6sser RM, Krumbach F, Corrales E, Andrieux G, Preisinger C, Liss F, Golzmann A, Boerries M, Becker K, Kn\u00fcchel R, Garczyk S. And L\u00fcscher B. Multidimensional omics reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal-like and malignant urothelial cells. Mol Oncol. 2025.","DOI":"10.1002\/1878-0261.70019"},{"key":"7386_CR44","doi-asserted-by":"publisher","first-page":"6117","DOI":"10.1038\/s41467-023-41658-z","volume":"14","author":"K Zheng","year":"2023","unstructured":"Zheng K, Sha N, Hou G, Leng Z, Zhao Q, Zhang L, He L, Xu M, Jiang Y, Chen T. IGF1R-phosphorylated PYCR1 facilitates ELK4 transcriptional activity and sustains tumor growth under hypoxia. Nat Commun. 2023;14:6117.","journal-title":"Nat Commun"},{"key":"7386_CR45","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s42255-022-00582-0","volume":"4","author":"EJ Kay","year":"2022","unstructured":"Kay EJ, Paterson K, Riera-Domingo C, Sumpton D, D\u00e4britz JHM, Tardito S, Boldrini C, Hernandez-Fernaud JR, Athineos D, Dhayade S, Stepanova E, Gjerga E, Neilson LJ, Lilla S, Hedley A, Koulouras G, McGregor G, Jamieson C, Johnson RM, Park M, Kirschner K, Miller C, Kamphorst JJ, Loayza-Puch F, Saez-Rodriguez J, Mazzone M, Blyth K, Zagnoni M, Zanivan S. Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix. Nat Metab. 2022;4:693\u2013710.","journal-title":"Nat Metab"},{"key":"7386_CR46","doi-asserted-by":"publisher","first-page":"e70045","DOI":"10.1002\/ctm2.70045","volume":"14","author":"H Wang","year":"2024","unstructured":"Wang H, Xu M, Zhang T, Pan J, Li C, Pan B, Zhou L, Huang Y, Gao C, He M, Xue Y, Ji X, Zhang X, Wang N, Zhou H, Wang Q, Li JZ. PYCR1 promotes liver cancer cell growth and metastasis by regulating IRS1 expression through lactylation modification. Clin Transl Med. 2024;14:e70045.","journal-title":"Clin Transl Med"},{"key":"7386_CR47","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.7150\/jca.61498","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang H, Mao W, Lou W, Jin D, Wu W, Wang D, Kuang T, Rong Y, Xu X, Zhang L. PYCR1: A potential prognostic biomarker in pancreatic ductal adenocarcinoma. J Cancer. 2022;13:1501\u201311.","journal-title":"J Cancer"},{"key":"7386_CR48","doi-asserted-by":"publisher","first-page":"194829","DOI":"10.1016\/j.bbagrm.2022.194829","volume":"1865","author":"S Xiao","year":"2022","unstructured":"Xiao S, Yao X, Ye J, Tian X, Yin Z, Zhou L. Epigenetic modification facilitates proline synthase PYCR1 aberrant expression in gastric cancer. Biochim Biophys Acta Gene Regul Mech. 2022;1865:194829.","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"7386_CR49","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.biopha.2018.12.089","volume":"111","author":"D Wang","year":"2019","unstructured":"Wang D, Wang L, Zhang Y, Yan Z, Liu L, Chen G. PYCR1 promotes the progression of non-small-cell lung cancer under the negative regulation of miR-488. Biomed Pharmacother. 2019;111:588\u201395.","journal-title":"Biomed Pharmacother"},{"key":"7386_CR50","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cmet.2016.10.011","volume":"24","author":"L Yang","year":"2016","unstructured":"Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, Nagaraja AS, Haemmerle M, Kyunghee N, Derichsweiler M, Plackemeier T, Mercado-Uribe I, Lopez-Berestein G, Moss T, Ram PT, Liu J, Lu X, Mok SC. Sood AK and Nagrath D. Targeting stromal glutamine synthetase in tumors disrupts tumor Microenvironment-Regulated cancer cell growth. Cell Metab. 2016;24:685\u2013700.","journal-title":"Cell Metab"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07386-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07386-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07386-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:02:52Z","timestamp":1763035372000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07386-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7386"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07386-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"26 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Ethics Committee of Peking University First Hospital (Approval No. 2020\u2013303) and was carried out in accordance with institutional guidelines and the ethical principles of the Declaration of Helsinki (1964) and its subsequent amendments. Given the retrospective design of the study, the requirement for informed consent was waived by the Ethics Committee. Animal experiments were approved by the Animal Care Committee of Peking University First Hospital (Ethical approval number: J2025011).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final version of the manuscript and consent to its publication in the\n                      Journal of Translational Medicine\n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1277"}}